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Abstract
Objectives. Therapeutic monitoring of sirolimus and everolimus is necessary in order to minimize adverse side-effects and to
ensure effective immunosuppression. A sirolimus-dosing model using the concentration/dose ratio has been previously
proposed for kidney transplant patients, and the aim of our study was the evaluation of this single model for the prediction of
trough sirolimus and everolimus concentrations.
Methods. Trough steady-state sirolimus concentrations were determined in several blood samples from each of 7 kidney and 9
liver maintenance transplant recipients, and everolimus concentrations from 20 kidney, 17 liver, and 3 kidney/liver
maintenance transplant recipients. Predicted sirolimus and everolimus concentrations (Css), corresponding to the doses
(D), were calculated using the measured concentrations (Css0) and corresponding doses (D0) on starting the study:
Css = (Css0)(D)/D0.
Results. The diagnostic efﬁciency of the predicting model for the correct classiﬁcation as subtherapeutic, therapeutic, and
supratherapeutic values with respect to the experimentally obtained concentrations was 91.3% for sirolimus and 81.4% for
everolimus in the kidney transplant patients. In the liver transplant patients the efﬁciency was 69.2% for sirolimus and 72.6%
for everolimus, and in the kidney/liver transplant recipients the efﬁciency for everolimus was 67.9%.
Conclusions. The model has an acceptable diagnostic efﬁciency (>80%) for the prediction of sirolimus and everolimus
concentrations in kidney transplant recipients, but not in liver transplant recipients. However, considering the wide ranges
found for the prediction error of sirolimus and everolimus concentrations, the clinical relevance of this dosing model is weak.
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Introduction
Sirolimus (Rapamune , Wyeth Pharmaceuticals,
Madison, NJ, USA) and everolimus (Certican ,
Novartis Pharma AG, Basel, Switzerland), a derivative
of sirolimus with a 2-hydroxyethyl chain at position
40, are actually widely used as immunosuppressant
agents in solid organ transplant recipients. Both drugs
have a narrow therapeutic index, poor correlations
between the doses and blood concentrations, and
therapeutic monitoring is necessary in order to min-
imize adverse side-effects and to ensure effective
immunosuppression (1–4). As the highest proportion
of sirolimus and everolimus is found within erythro-
cytes,EDTA-anticoagulated wholebloodis theappro-
priate matrix for the determination of the trough
concentration, which presents a good correlation
with the area under the concentration-time curve
(1–5). Therapeutic trough concentration ranges of
5–15 mg/L for sirolimus (1–3,6) and 3–8 mg/L for
everolimus (4,7) are generally accepted.
An algorithm based on the concentration/dose
ratio, using a previous trough level determination
corresponding to a particular dose for the prediction
of subsequent dosages of sirolimus in kidney trans-
plant patients, has been previously proposed by
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DOI: 10.3109/03009730903291026Wyeth Pharmaceuticals (8). The aim of our study was
the determination of the intra- and interindividual
variability of sirolimus and everolimus clearance in
renal and liver transplant recipients, in order to eval-
uate the diagnostic efﬁciency and clinical usefulness
of the concentration/dose ratio for the prediction of
steady-state trough concentrations (or dosage regi-
mens) of both drugs.
Patients and methods
A total of 16 patients treated with sirolimus were
studied, with an age (mean ± SEM) of
53.9 ± 3.8 years (range 19–75 years), of which 7
(5 men and 2 women) were maintenance renal trans-
plant recipients, and 9 (men) were maintenance liver
transplant recipients. In 4 cases, sirolimus was admin-
istered in monotherapy, in 4 tacrolimus was associated,
in 3 tacrolimusþmycophenolate, in 3 mycophenolate,
in 1 cyclosporin, and in 1 cyclosporinþtacrolimus. The
group treated with everolimus was comprised of 40
patients with an age of 56.7 ± 1.5 years (range 27–
72 years), of which 20 (11 men and 9 women) were
maintenance renal transplant patients, 17 (16 men and
1 woman) were maintenance liver transplant patients,
and 3 (men) were kidney and liver recipients. In 5 cases,
everolimus was administer e di nm o n o t h e r a p y ,i n5
tacrolimus was associated, in 13 tacrolimusþmycophe-
nolate, in 12 mycophenolate, in 1 cyclosporin, and in 4
cyclosporinþmycophenolate. Several blood samples
from each of the different transplant patients were taken
prior to the next dose of sirolimus or everolimus, and at
least after a 10-day period without any modiﬁcation of
the dosage or concomitant administered drugs. Con-
sequently, the blood concentrations of both immuno-
suppressant drugs correspond to the steady-state trough
levels (Css). The study was carried out according to the
good practice rules for investigation in humans of the
Conselleria de Sanidade (Regional Ministry of Health)
o ft h eX u n t ad eG a l i c i a ,S p a i n .
Sirolimus determination was carried out using the
IMx sirolimus microparticle enzyme immunoassay
(MEIA) from Abbott Laboratories (Abbott Park, IL,
USA) according to the manufacturer’ss p e c i ﬁcations.
The concentrations of sirolimus were also determined
by high-performance liquid chromatography (HPLC)
with UV detection (9). The determination of ever-
olimus was carried out using the IMx sirolimus
MEIA (Abbott Laboratories), as previously described
(10). The imprecision of the methods used for the
determination of both immunosuppressive agents may
be considered as very satisfactory, with within- and
between-run variation coefﬁcients of 3.4%–8.6% using
MEIA and 3.9%–11.9% using HPLC for sirolimus
determination (9), and 2.8%–7.3% using MEIA for
everolimus determination (10). Sirolimus and ever-
olimus clearance (CL) was estimated using the equa-
tion (11): CL = (F)(D/t)/Css, where F corresponds to
the bioavailability (0.15 for sirolimus (6) and 0.16 for
everolimus (7) were considered), D is the dose, t the
dosing interval, and Css the whole-blood concentra-
tion. As trough rather than mean concentrations were
used, the reported CL may represent overestimates of
the actual values. For the prediction of sirolimus and
everolimus steady-state trough concentrations, the
measured concentrations on starting the study
(Css0), corresponding to the particular doses (D0),
were used for the calculation of the predicted concen-
trations (Css) corresponding to other doses (D) using
the expression: Css = (Css0)(D)/D0. The calculation of
the prediction error was made using the equation:
((Css-Css0)/Css0) 100,andexpressed asapercentage.
Serum levels of albumin, bilirubin, creatinine, urea,
alanineaminotransferase(ALT),aspartateaminotrans-
ferase (AST), cholinesterase (ChE), alkaline phospha-
tase (ALP), and gamma glutamyltransferase (GGT)
were determined in an Advia 2400 Chemistry System
(Siemens Healthcare Diagnostics Inc., Newark, DE,
USA). The glomerular ﬁltration rate (GFR) was esti-
mated using the six-variable (age, sex, race, and serum
creatinine, urea, and albumin concentrations) Modiﬁ-
cation of Diet in Renal Disease formula (12).
Statistical analysis was carried out using the Stat-
Graphics Plus (v. 5.0) package. The Shapiro-Wilks
method was used to check the distribution of data,
and Pearson’s correlation coefﬁcient was used when
the data had a Gaussian distribution, otherwise,
Spearman’s correlation coefﬁcient was used. The
regression analysis was made using the Passing-
Bablock non-parametric method. In accordance
with the proposed validation criteria of analytical
methods for the quantitative determination of drugs
and their metabolites, the acceptance criterion for
accuracy is a deviation of no more than 15% from
the nominal value (13,14).
Results
Figure 1 shows the correlation and regression found
between the values obtained for sirolimus CL using
the blood concentrations determined by MEIA and
HPLC. The correlation obtained has to be considered
as highly satisfactory, although, as would be expected
taking into account the sirolimus-metabolite cross-
reactivity with the antibody of the immunoassay used
(9), the sirolimus CL obtained from the MEIA data is
signiﬁcantlylower(mean 3.1± 0.2 L/h, median2.6L/h
versus mean 3.6 ± 0.2 L/h, median 3.1 L/h, P < 0.001).
126 L. Bouzas et al.The results indicated below for sirolimus CL
were calculated based on the concentrations deter-
mined by MEIA; however, the use of the CL values
obtained from HPLC concentrations led to the same
conclusions, without providing any data of further
interest.
Table I shows the results obtained for CL of sir-
olimus and everolimus in the groups of kidney and
liver transplant patients. In the kidney transplant
patients, an intraindividual variability for sirolimus
CL was found of 25.6%, and an interindividual var-
iability of 44.2%, and for everolimus CL 20.0% and
45.0%, respectively. In the liver transplant patients,
sirolimus CL presented an intraindividual variability
of 44.4% and an interindividual variability of 86.0%,
and everolimus CL 23.0% and 40.0%, respectively. In
the patients with kidney/liver transplants, an intrain-
dividual variability for everolimus CL was found of
42.7% and an interindividual variability of 84.1%.
As shown in Figure 2, a signiﬁcant negative corre-
lation was found for the CL with the blood concen-
trations of sirolimus (A) and everolimus (C). Also,
signiﬁcant correlations were found for sirolimus CL
with bilirubin (r =  0.210, P < 0.05), and for ever-
olimus CL with bilirubin (r =  0.253, P < 0.001),
AST (r =  0.360, P < 0.001), ALT (r =  0.283,
P < 0.001), GGT (r =  0.285, P < 0.001), ALP
(r =  0.217), and ChE (r = 0.266, P < 0.001). Sta-
tistical signiﬁcance was not achieved in the correlation
of sirolimus CL and everolimus CL with the albumin
concentration. There was no signiﬁcant difference in
sirolimus CL (mean 2.6 ± 0.2 L/h, median 2.6 L/h
versus mean 3.3 ± 0.4 L/h, median 2.8 L/h) or ever-
olimus CL (mean 3.6 ± 0.1 L/h, median 3.6 L/h
versus mean 4.4 ± 0.5 L/h, median 3.5 L/h), and
sirolimus concentrations (mean 7.6 ± 0.4 m/L, median
7.6 mg/L versus mean 8.8 ± 0.6 mg/L, median 9.3 mg/
L) or everolimus (mean 4.6 ± 0.1 mg/L, median 4.2
mg/L versus mean 4.3 ± 0.3 mg/L, median 3.8 mg/L)
between the patients with serum triglyceride concen-
trations below and above 2 mmol/L.
Figure 2 shows the correlation found between the
predicted concentrations using the model indicated
above and the concentrations obtained experimen-
tally for sirolimus (B) and everolimus (D). The error
(deviation) of the mean predicted concentrations with
regard to those obtained, both for sirolimus (mean
7.7 ± 0.3 mg/L, median 7.5 m/L versus mean 7.5 ± 0.2
mg/L, median 6.8 mg/L) and for everolimus (mean
4.4 ± 0.1 mg/L, median 4.0 mg/L versus mean 4.3 ± 0.1
mg/L, median 4.2 mg/L), was less than 15% and
therefore acceptable according to the accuracy crite-
rion used (13,14). However, wide ranges were
obtained for the prediction error of the sirolimus
and everolimus concentrations in the total group
( 58.9% to 261.1% and  70.8% to 442.8%), and
also in the kidney ( 48.5% to 75.0% and  70.8% to
107.8%), liver ( 58.9% to 261.1% and  55.0 to
114.8%), and kidney/liver ( 44.1% to 442.9% for
everolimus) transplant recipient groups. The mean
intra- and interindividual variability of the immuno-
suppressive drugs CL and the prediction error
obtained in the four patients treated in monotherapy
with sirolimus (two renal and two liver transplant
recipients) and ﬁve with everolimus (three renal
and two liver transplant recipients) were only slightly
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Figure1. Correlation and regression between the sirolimus
clearance (CL) values obtained using the blood concentrations
determined by microparticle enzyme immunoassay (MEIA) and
high-performance liquid chromatography (HPLC) in the kidney
(*) and liver (.) transplant recipients.
Table I. Trough concentrations (Css) and clearance (CL) of
sirolimus and everolimus in kidney and liver transplant recipients.
n Kidney transplant n Liver transplant
Sirolimus:
Css (mg/L) 52 8.1 ± 0.4 (8.4)
a 61 7.2 ± 0.5 (6.3)
a
CL (L/h) 52 3.0 ± 0.2 (2.8) 61 3.2 ± 0.3 (2.3)
GFR (mL/
min/1.73 m
2)
52 49.4 ± 3.0 (50.9)
b 61 66.6 ± 4.0 (72.4)
b
Everolimus:
Css (m/L) 169 4.5 ± 0.1 (4.2) 80 4.6 ± 0.2 (3.9)
CL (L/h) 169 3.7 ± 0.1 (3.8)
b 80 3.1 ± 0.1 (2.9)
b
GFR (mL/
min/1.73 m
2)
169 45.7 ± 1.2 (42.9) 80 42.3 ± 1.9 (45.0)
aP < 0.05.
bP < 0.01.
GFR = glomerular ﬁltration rate.
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kidney and liver transplant patients.
In the total number of cases studied, the concor-
dance in the classiﬁcation as subtherapeutic, thera-
peutic, and supratherapeutic levels between predicted
and obtained concentrations was 79.6% for sirolimus
and 77.4% for everolimus. In the kidney transplant
recipients this concordance was 91.3% for sirolimus
and 81.4% for everolimus; however, in the liver trans-
plant recipients the concordance was lower, 69.2% for
sirolimus and 72.6% for everolimus, and in the
kidney/liver transplant recipients the concordance
obtained for everolimus was 67.9%.
Discussion
Variations in sirolimus and everolimus absorption and
CL result in a wide range of trough concentrations
among patients receiving the same dose. The combi-
nation of cyclosporin and the two mTor inhibitors
requires a reduction of both drugs due to a well-
established pharmacokinetic drug interaction;
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Figure2. Relationship of the sirolimus and everolimus clearance (CL) with its blood concentrations (A, C), and between the predicted and
obtained sirolimus and everolimus concentrations (B, D) in the kidney (*), liver (.), and kidney/liver (D) transplant recipients.
128 L. Bouzas et al.however, to date no signiﬁcant inﬂuence of mycophe-
nolate on sirolimus/everolimus exposure has been
reported, and with regard to the potential tacrolimus
interaction, contradictory ﬁndings have been pub-
lished (15).
Although intestinal absorption may not be signiﬁ-
cantly affected in hepatic dysfunction, patients with
liverdisease showeddecreasedCLofsirolimus (16,17)
and everolimus (18). As shown in Table I, for siroli-
mus CL no signiﬁcant difference was found between
the groups of kidney and liver transplant patients;
however, the group of kidney transplant patients had
as i g n i ﬁcantly higher concentration of sirolimus
(P < 0.05) and, in line with the results shown
in Figure 2A, this could be masking a possible statis-
tical signiﬁcance of the difference between the siroli-
mus CL of both groups. It should also be taken into
account that the group of kidney transplant patients
hadanestimatedGFRthatwassigniﬁcantlylowerthan
the group of liver transplant patients (P < 0.001), and
renal insufﬁciency alters intestinal, renal, and hepatic
drug metabolism (19,20). A signiﬁcantly higher CL
was found for everolimus in the group of kidney
transplant recipients (P < 0.001), without the presence
of any signiﬁcant difference between the everolimus
concentrations or estimated GFR of the groups of
kidney and liver transplant patients (Table I).
Recently it has been noted that serum ALP and
GGT activities are quite sensitive in predicting biliary
tract complications post liver transplantation, and also
that AST, ALT, and bilirubin were not of any clinical
signiﬁcance in diagnosing these complications (21).
As previously mentioned, statistically signiﬁcant neg-
ative correlations were found for sirolimus CL with
bilirubin and everolimus CL with bilirubin, ALP,
GGT, AST, and ALT, although with modest corre-
lation coefﬁcients.
In de novo heart transplant recipients, the sirolimus
apparent clearance (CL/F) was 38% lower when the
triglyceride concentration was higher than 2 mmol/L
(22); however, in our maintenance kidney and liver
transplant patients a signiﬁcant difference was not
obtained for the CL of sirolimus and everolimus
between the cases with triglyceride levels lower or
greater than 2 mmol/L.
As shown in Figure 2 (A, C), CL values vary with
sirolimus and everolimus concentration, suggesting
that the metabolism of both drugs tends toward
saturation as the concentration increases. However,
the use of a concentration/dose ratio model to predict
the dosage required to achieve a desired steady-state
concentration of sirolimus from previous concentra-
tions and corresponding doses for the samepatient (8)
assumes a linear relationship between sirolimus doses
and concentrations (ﬁrst-zero-order kinetics).
Figure 2 (B, D) shows the relationships found
between the predicted concentrations and those
obtained for sirolimus and everolimus. The diagnostic
efﬁciency of a laboratory test is deﬁned as the percent-
age of all results that are true, and as a general rule a
test is probably not worth doing if its efﬁciency is less
than 80% (23). As a result, the efﬁciency of the
predictive model is acceptable in the kidney transplant
recipients, with a concordance between the predicted
concentrations and those obtained as subtherapeutic,
therapeutic, and supratherapeutic concentrations of
91.3% for sirolimus and 81.4% for everolimus. The
intraindividual variability obtained for everolimus CL
was slightly lower than that of sirolimus CL, but the
diagnostic efﬁciency was greater in the prediction of
sirolimus levels due to its greater therapeutic concen-
tration range. In any case, the wide range found for the
prediction error of the sirolimus and everolimus con-
centrationsisanimportantdisadvantagefortheroutine
application of this dosing model in clinical practice. In
the groups of liver and kidney/liver transplant recipi-
ents, with a greater intraindividual variability for the
CL values, the diagnostic efﬁciency found for both
sirolimus and everolimus is unacceptable (<80%).
In conclusion, the dosing model using the concen-
tration/dose ratio would have an acceptable diagnostic
efﬁciency for the dosage adjustment of sirolimus and
everolimus in kidney transplant recipients, but not in
liver transplant patients. However, according to our
results, the clinical usefulness of this predictive model
is weak.
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